BIOTECH · ArriVent's lung cancer drug fails key trial, stock halves
Firmonertinib missed its main goal in a pivotal lung cancer trial, and ArriVent's stock lost more than half its value within hours.
@thedailyfathom.bsky.socialExplore
@thedailyfathom.bsky.social